{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/dyspepsia-proven-peptic-ulcer/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"c6e3fda6-22f9-51b3-94d8-fc248cda56bd","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field b464fdc8-252c-40de-8668-90e037e49820 --><h2>Changes</h2><!-- end field b464fdc8-252c-40de-8668-90e037e49820 -->","summary":null,"htmlStringContent":"<!-- begin item 83b1f22e-56a2-46d8-8eb6-2e3c190e7028 --><!-- begin field 7fa43698-8e95-45fe-8467-85b59df3e632 --><p><strong>October 2019 </strong>— minor update. Topic updated in line with NICE guideline, 2019 update, <em>Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-peptic-ulcer/references/\">NICE, 2019</a>].</p><p><strong>October 2018 </strong>— minor update. Adverse effects updated within prescribing information - metronidazole. </p><p><strong>September 2017 </strong>— minor update. SPC update on quinolones to align all CKS topics prescribing advice. Prostatitis - chronic, Gonorrhoea, Pyelonephritis, Diarrhoea - prevention and advice for travellers, Dyspepsia - unidentified cause, Dyspepsia - proven functional, Dyspepsia - proven peptic ulcer, Diverticular disease, Gastroenteritis and Scrotal pain and swellings. </p><p><strong>April to May 2017 </strong>— reviewed. A literature search was conducted in February 2017 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials since the last revision of this topic. The recommendations on primary care management and referral have been updated in line with the National Institute for Health and Care Excellence (NICE) clinical guideline <em>Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management </em>(2014). The lower age limit has been changed from 16 to 18 years. The content has been amended to include second-line drug regimens for <em>Helicobacter pylori</em> eradication, in line with the updated NICE guidance. The prescribing information section has been expanded to include antibiotics recommended for <em>H. pylori</em> eradication. The topic has also undergone significant restructuring.</p><!-- end field 7fa43698-8e95-45fe-8467-85b59df3e632 --><!-- end item 83b1f22e-56a2-46d8-8eb6-2e3c190e7028 -->","topic":{"id":"4d7c8c68-3a8f-5975-99a6-50cb32ce9c94","topicId":"3ad099a3-2ca3-4327-9bda-99105ccbd251","topicName":"Dyspepsia - proven peptic ulcer","slug":"dyspepsia-proven-peptic-ulcer","lastRevised":"Last revised in October 2019","chapters":[{"id":"b126bb0b-6cc6-5fb5-a165-08590aab0070","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"7966dab4-9ee2-5d7d-8253-890904345546","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"863af072-467d-558f-a5a4-938251ca4b70","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"c6e3fda6-22f9-51b3-94d8-fc248cda56bd","slug":"changes","fullItemName":"Changes"},{"id":"d90954aa-bfcf-53f9-bf54-94b6f90fc75f","slug":"update","fullItemName":"Update"}]},{"id":"b8e40cd5-8e95-5335-9d56-292936d0d7a7","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"b8925c36-3dae-5ec7-8277-83b343cdc753","slug":"goals","fullItemName":"Goals"},{"id":"99d05347-f238-52f8-a91d-6367fc2a4c84","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"2658a735-068a-5b5a-b9de-83da5c0d4c04","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"6e095fbb-fc3e-5b4e-aec2-bf80df353e31","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"90cb6b5a-e54b-565d-809f-76ac723d4bba","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"3a584a99-78fc-5b5b-8ae6-b14250c00325","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"df3e0e6a-10b7-5ced-9c05-dff646629460","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"f35e4de1-c942-50cb-aef3-91b3c4def480","slug":"definition","fullItemName":"Definition"},{"id":"a8810be9-e85c-535f-9ccd-50aee78e9c8b","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"da86cd41-e515-572c-aa44-9330eba9ac28","slug":"prevalence","fullItemName":"Prevalence"},{"id":"f5dd15bb-7399-5245-8f59-87a9790a59a7","slug":"complications","fullItemName":"Complications"},{"id":"126a2719-f8ba-5188-ac87-dcecfe57ea0e","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"6278e7c4-7eeb-5045-b77c-00b84f08b040","fullItemName":"Management","slug":"management","subChapters":[{"id":"be22af5a-19ce-5791-8415-1297662b5e10","slug":"management-proven-peptic-ulcer","fullItemName":"Scenario: Management - proven peptic ulcer"}]},{"id":"6dc780ed-17b4-53f7-b5b1-9ce5899e505f","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"967aa284-35b6-5f7c-838f-5dbbda36ac93","slug":"proton-pump-inhibitors","fullItemName":"Proton pump inhibitors"},{"id":"e2e731b3-6cb9-5268-b8c9-9839738dcf7f","slug":"h2-receptor-antagonists","fullItemName":"H2-receptor antagonists"},{"id":"59f31401-2de6-5276-9ffc-800e8e519e95","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"9eb0d371-d052-5fd9-ba58-45fcf40cbbfe","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"d2ff9ee7-1022-5cb2-aa78-f65bf08be543","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"b8602cfd-a10c-5663-b691-a8ca11b0ed81","slug":"tetracycline","fullItemName":"Tetracycline"},{"id":"f17ce37f-6d62-5780-b8d9-9426dcd13e56","slug":"levofloxacin","fullItemName":"Levofloxacin"},{"id":"9eb2f48d-68e2-51ca-acee-8ae753fa0e83","slug":"bismuth","fullItemName":"Bismuth"}]},{"id":"5d80e758-2b4f-50bd-957d-658701dadd77","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"5d902b88-104e-572b-9dcd-f4035f35a4c5","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"b954b837-c685-5f3f-b569-e2a1cc897ef4","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f1ddadd9-ccea-5965-9c2f-6e2848db1f33","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"49079197-90f7-5a71-9f31-cd48ba3d7e9b","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"201aafd4-5cd3-5f8d-9ac0-364e8cd95e53","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"ea362840-d561-5944-8292-1f1c7a1feef4","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"c1e4fdd8-fd8a-5191-aaf4-fb43c1ed5a7f","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"863af072-467d-558f-a5a4-938251ca4b70","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"4eb8acae-c84d-5b80-a1c0-96b10af7076f","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field fb30e80f-0a81-4450-b7ea-a4b2ba40f451 --><h3>Previous changes</h3><!-- end field fb30e80f-0a81-4450-b7ea-a4b2ba40f451 -->","summary":null,"htmlStringContent":"<!-- begin item 96a92cca-a765-4ae9-9315-2cef8e8aafdf --><!-- begin field 7039fd59-a204-4e2a-afd7-5c9b2c375033 --><p><strong>December 2016</strong> — minor update. Subacute cutaneous lupus erythematosus has been added as a very infrequent adverse effect of proton pump inhibitors, in line with a Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update (2015).</p><p><strong>July 2015 </strong>— minor update. The prescribing information section for clarithromycin has been re-written for clarity.</p><p><strong>February 2015 </strong>—<strong> </strong>minor update. The prescribing information section was updated to provide additional information regarding the possible drug interaction of clarithromycin with lovastatin or simvastatin in line with the manufacturer's Summary of Product Characteristics (2014).</p><p><strong>November 2012 </strong>—<strong> </strong>reviewed. A literature search was conducted in October 2012 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. No changes to clinical recommendations have been made.</p><p><strong>October 2012 </strong>— minor update. The 2012 QIPP options for local implementation have been added to this topic (2012).</p><p><strong>September 2012 </strong>— minor amendment to text to clarify that testing for <em>Helicobacter pylori </em>should be done before proton pump inhibitor (PPI) treatment is started.</p><p><strong>January 2012 </strong>—<strong> </strong>minor update. Information from the manufacturer's Summary of Product Characteristics (2011) about the possible drug interaction between pantoprazole and warfarin has been added to the prescribing information section. Information from the British National Formulary (2011) about the potentially serious drug interaction between PPIs and protease inhibitors (atazanavir and saquinavir) has also been added. Issued in January 2012.</p><p><strong>May 2011 </strong>— minor update. The 2010/2011 QIPP options for local implementation have been added to this topic (2011). Issued in June 2011.</p><p><strong>March 2011 </strong>— topic structure revised to ensure consistency across CKS topics — no changes to clinical recommendations have been made.</p><p><strong>July 2009 </strong>— minor update. The Medicines and Healthcare products Regulatory Agency (MHRA) has issued advice on the interaction between clopidogrel and PPIs (2009). Healthcare professionals are advised to avoid concomitant use of these drugs unless considered essential. Issued in July 2009.</p><p><strong>November 2008 </strong>— minor typographical corrections.</p><p><strong>March to June 2008 </strong>— converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. There are no major changes to the recommendations.</p><p><strong>May 2007 </strong>— minor update. HeliClear triple pack discontinued and prescriptions removed. Issued in May 2007.</p><p><strong>October 2005 </strong>— minor update. HeliMet triple pack discontinued and prescriptions removed. Issued in November 2005.</p><p><strong>July 2005 </strong>— updated to incorporate the <em>Referral guidelines for suspected cancer </em>published by the National Institute for Health and Care Excellence (2005). Issued in July 2005.</p><p><strong>December 2004 </strong>— reviewed and updated to incorporate the National Institute for Health and Care Excellence (NICE) guideline on <em>Dyspepsia </em>(August 2004). Validated in March 2005 and issued in April 2005.</p><p><strong>July 2003 </strong>— updated to incorporate information from the Scottish Intercollegiate Guidelines Network (SIGN) guideline <em>Dyspepsia </em>(March 2003). Validated in September 2003 and issued in October 2003.</p><p><strong>November 2000 </strong>— reviewed and updated to incorporate the Technology appraisal guidance <em>Guidance on the Use of Proton Pump Inhibitors (PPIs) in the Treatment of Dyspepsia</em> issued by the National Institute for Health and Care Excellence (July 2000), and the Department of Health referral guidelines for suspected upper gastrointestinal cancers. Validated in November 2000 and issued in December 2000.</p><p><strong>June 1998 </strong>— written.</p><!-- end field 7039fd59-a204-4e2a-afd7-5c9b2c375033 --><!-- end item 96a92cca-a765-4ae9-9315-2cef8e8aafdf -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}